TQH3906 not checked
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “TQH3906 Capsules is an inhibitor that targets tyrosine kinase 2 (TYK2).”In the company’s words, NCT07724366 on ClinicalTrials.gov
- Main trialPhase 3
- “This study is a multicenter, randomized, double-blind, placebo- and active-controlled Phase III clinical trial sponsored by Nanjing Shunxin Pharmaceutical Co., Ltd., a subsidiary of Chiatai Tianqing Pharmaceutical Group. The study aims to evaluate the efficacy and safety of once-daily oral TQH3906 capsules (24 mg) in adult participants with moderate to severe plaque psoriasis. TQH3906 is a highly selective TYK2 allosteric inhibitor targeting the JH2 domain, which blocks the IL-23 and Type I interferon inflammatory pathways. Approximately 400 eligible participants aged 18-75 years will be…”In the company’s words, NCT07724366 on ClinicalTrials.gov
Other drugs for Psoriasis
- ZasocitinibTakeda · Phase 3
- BimekizumabUCB Biopharma SRL · Phase 3
- PiclidenosonCan-Fite BioPharma · Phase 3
- Total coumarin creamPsoriasis Research Institute of Guangzhou · Phase 3
- RisankizumabAbbVie · Phase 3
- PonesimodVanda Pharmaceuticals · Actelion · Phase 3
Coming up4
- Jul 2027Phase 1 trial completes · ClinicalTrials.gov
- Aug 2027Phase 2 trial completes · ClinicalTrials.gov
- Sep 2027Phase 3 trial completes · ClinicalTrials.gov
- Nov 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Sep 2027 | A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis | |
| Phase 2Recruiting | Aug 2027 | A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis | |
| Phase 2Recruiting | Nov 2027 | A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus | |
| Phase 1Recruiting | Jul 2027 | Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease | |
| Phase 2Completed | 3 Nov 2025 | Treatment of Moderate to Severe Plaque Psoriasis | |
| Phase 1Completed | 27 Apr 2025 | A Clinical Trial of TQH3906 Capsules in Healthy Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026